Ira C. Spector

Company: SFA Therapeutics

Job title: Chief Executive Office

Seminars:

SFA-002: A Novel Oral Drug for Treating Autoimmune Disease: Results in Psoriasis 11:00 am

Outlining SFA-002 mechanism of action by immunomodulation over immunosuppression Preclinical, phase Ia and phase Ib efficacy findings Safety profile Durable responses Special populations – scalp/palmoplantar psoriasis cohorts Differentiation strategy: convenience, cost, and multi-pathway modulationRead more

day: Day Two AM